Reevaluating Beta-Blocker Use in Heart Attack Patients: Benefits and Risks
Two recent trials on beta-blockers in post-MI patients with preserved or mildly reduced ejection fraction show mixed results, but meta-analyses suggest potential benefits for those with ejection fraction between 40% and 49%. This challenges the routine use of beta-blockers in all post-MI patients and advocates for a more personalized approach based on ejection fraction and individual risk factors.